Árias-Puente L, Garza-de-la-Peña E, Velásquez-Ramírez G, Martínez-Barreda C, Ruiz-Argüelles GJ

Language: Spanish
References: 15
Page: 169-172
PDF size: 66.71 Kb.

ABSTRACT

Background: Invasive aspergillosis is a fungal necrotizing infection that occurs in immunocompromised patients. It causes vascular thrombosis, ischemic necrosis and cavitary lesions. The incidence ranges from 5-20% in high risk groups. Histologically, broad hyphae displayed in a radially fashion and neutrophils infiltration are founded. The diagnosis of invasive aspergillosis should be based on clinical suspicion and confirmation through direct observation of the clinical sample, cultures and by detection of the galactomannan antigen in serum.
Material and methods: Patients undergone bone marrow transplantation at Centro de Hematología y Medicina Interna of Puebla city between july 2007 and august 2009 were selected retrospectively by patient personal file consultation. A total of 27 patients were included, all of them presented hematologic neoplasms, neutropenia and fever. Serum samples from these patients were analyzed by the enzymatic immunoassay commercial kit Platelia^® Aspergillus (Bio-Rad^®, France).
Results: The presence of galactomannan antigen was detected in 14.8% (n=4) from the patient study group, of which 75% (n=3) died from invasive aspergillosis.
Conclusions: Serum galactomannan antigen identification in immunocompromised patients represents a bad prognostic factor.

REFERENCES

1. Kawazu M, Kanda Y, Nannya Y. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzymelinked immunosorbent assay for galactomannan, and a (1—13)-beta- D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004;42:2733–2741.

2. Kwak EJ, Husain S, Obman A. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004;2:435–438.

3. Ulusakarya A, Chachaty E, Vantelon JM. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000;1:111-116.

4. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho- alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003;121:448-457.

5. Boutboul F, Alberti C, Leblanc T. Invasive aspergillosis in allogeneic stemcell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939-943.

6. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297–1306.

7. Verweij PE, Brinkman K, Kremer HPH. Aspergillus meningitis: diagnosis bynon-culture-based microbiological methods and management. J Clin Microbiol 1999;37:1186-1189.

8. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2005;33:1824-1833.

9. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8(9):512-520.

10. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.

11. Boutboul F, Alberti C, Leblanc T. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939-943.

12. Lombardi G, Farina C, Andreoni S. Multicenter evaluation of an enzyme immunoassay (Platelia® Aspergillus) for the detection of Aspergillus antigen in serum. Mycopathologia 2002;155:129-133.

13. Pinel C, Fricker-Hidalgo H, Lebeau B. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003;41:2184-2186.

14. Ascioglu S, de Paw B, Bennett JE. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.

15. Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH, et al. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution. Clin Infect Dis 2000;31:859-68.